• There are several AP binding sites in the sequence of

  2025-01-31

  

  There are several AP-1 s6 kinase in the sequence of TIMP-1 promoter [18,19]. EBV could up-regulate TIMP-1 expression by binding to the AP-1 site in the TIMP-1 promoter [18]. IL-32, a newly multi-function cytokine, could activate AP-1, NF-κβ, p38MAPK signal pathways, and induce cytokine expressions,

• br Materials and Methods br Results br Discussion

  2025-01-31

  

  Materials and Methods Results Discussion XHP is a traditional Chinese anti-cancer medicine that is widely used for the treatment and adjuvant treatment of breast cancer. XHP has been shown to induce apoptosis in various breast cancer ras inhibitor in vitro, including Hs578T, MCF-7, and MDA

• Interestingly we found that co treatment

  2025-01-31

  

  Interestingly, we found that co-treatment with losartan prevented the increased participation of ROS from NADPH oxidase on the contractile response to Phe observed in Hg-treated rats. Moreover, losartan also prevented the reduction in the endothelial NO modulation of this response found in treated a

• br Role of AR in models of neointima

  2025-01-31

  

  Role of AR in models of neointima formation Investigations into the pathogenesis of lesion formation have often used acute models of mechanical damage to assess the mechanisms regulating the fibro-proliferative response to arterial injury. Models of acute injury used for this purpose include: lig

• Safingol Hepatic inflammation and fibrosis are hallmarks of

  2025-01-31

  

  Hepatic Safingol and fibrosis are hallmarks of the NASH phenotype and are thought to occur in a subset of patients with NAFLD. While it is hypothesized that therapeutic lowering of hepatic lipids will be sufficient to improve hepatic fibrosis and inflammation secondarily, this remains controversial

• Treatment of all of the GYN cancer cells

  2025-01-27

  

  Treatment of all of the GYN cancer sq 22 in this study with ATRi not only reduced phosphorylation of Chk1 at Ser345 following genotoxic stress, but also phosphorylation of ATM. Loss of phospho-ATM following ATRi treatment is not likely due to non-specific targeting of ATM by ETP-46464 [28]. While A

• Several alterations have been or can

  2025-01-27

  

  Several alterations have been or can be associated to the decreased tolerance of steatotic liver to I/R injury. Previous studies demonstrated that upregulation of the mitochondrial uncoupling protein-2 (UP2) is strictly related to the increase of I/R injury in steatotic liver [4]. UPR induction is c

• Dopamine D1 receptor agonist Inflammations lead to the pertu

  2025-01-27

  

  Inflammations lead to the perturbation of aromatase enzyme [112], which normally is responsible for a broad array of critical functions. Chemotherapy targets this enzyme, so this treatment option is never side-effect-free and not fully-effective. Therefore, the mankind should be careful so as not to

• The lack of benefit in terms of

  2025-01-27

  

  The lack of benefit in terms of overall survival for antiangiogenic treatment was similar when antiangiogenic drug was used both as first and second-line therapy, and both in association with cytotoxic treatment or alone. Noteworthy, a trend for an inferior outcome was observed in the group of patie

• The Nagoya Heart Study enrolled patients

  2025-01-27

  

  The Nagoya Heart Study enrolled patients with hypertension and type 2 diabetes or impaired zilpaterol tolerance (12). Patients were randomized to valsartan- or amlodipine-based regimens with a BP target of ≤130/80 mmHg. The primary outcome was a composite of sudden cardiac death, myocardial infarct

• Ultracentrifugation of AD brain was reported to remove of

  2025-01-27

  

  Ultracentrifugation of AD tbca license was reported to remove >99.95% of Aβ, while only reducing seeding capacity by 70% (Langer et al., 2011). This suggests that the most potent seeding Aβ species are relatively small soluble oligomers rather than larger insoluble fibrils. It was also noted that t

• Second the phosphorylation events e g Thr and

  2025-01-27

  

  Second, the phosphorylation events (e.g., α-Thr172 and β-Ser108) needed for AMPK activation by small molecules binding at the ADaM or other sites remains unclear. Within the β-GBD, phosphorylation of β1-Ser108 was shown to be required for the activation by small molecules binding in the ADaM site, s

• Introduction AMP activated protein kinase AMPK is

  2025-01-27

  

  Introduction AMP-activated protein kinase (AMPK) is mainly known as a highly conserved and ubiquitously expressed energy sensor that is highly sensitive to changes in cellular energy levels (by sensing increases in AMP:ATP and ADP:ATP ratios) and makes appropriate adjustment to balance the consumpt

• Recently a Phase III study demonstrated that alectinib

  2025-01-26

  

  Recently, a Phase III study demonstrated that alectinib, the second-generation ALK inhibitor, might have a better response to ALK-rearrangement patients than crizotinib [10]. Should alectinib replace crizotinib as the frontline treatment for ALK-rearranged patients? Or should those patients be treat

• We have previously reported alterations

  2025-01-26

  

  We have previously reported alterations of the thymus in AChR-MG patients, especially in their germinal center jnk pathway (defined as CD19+CD38+ cells by flow cytometric analysis). First, we found that, in MG thymi, this subset failed to show the normal down-regulation of Bcl-2, suggesting that au

16010 records 17/1068 page Previous Next First page 上5页 1617181920 下5页 Last page